Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

NCT03492931 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03492931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03492931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2018
Completion date
May 7, 2019
Enrollment
21 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease